INIS
patients
100%
lymphomas
65%
diseases
46%
laboratories
45%
reviews
45%
stem cells
40%
thrombosis
28%
therapy
27%
doses
22%
central nervous system
21%
methotrexate
21%
detection
21%
mutations
21%
refractories
21%
fibrinogen
21%
systems analysis
21%
grafts
21%
utilities
21%
populations
21%
netherlands
21%
host
21%
immunosuppression
21%
congenital diseases
16%
testing
16%
thrombin
14%
management
14%
phenotype
14%
induction
13%
radiotherapy
13%
brain
13%
evaluation
11%
mortality
11%
risks
11%
surgery
10%
hazards
10%
chemotherapy
10%
death
9%
plasma
9%
fibrin
9%
comparative evaluations
9%
WHO
8%
molecules
7%
leukemia
7%
amino acids
7%
dimerization
7%
women
7%
proteins
7%
conformational changes
7%
adults
7%
standardization
7%
cyclosporine
7%
anticoagulants
7%
hemostatics
7%
etiology
7%
values
7%
investigations
7%
safety
6%
males
6%
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
46%
Overall Survival
26%
Primary Central Nervous System Lymphoma (PCNSL)
21%
High-dose Methotrexate (HD-MTX)
21%
Polytherapy
21%
Clinical Survival
21%
Clinical Characteristics
21%
Consolidation Therapy
21%
Survival Outcomes
21%
Hypodysfibrinogenemia
21%
Valemetostat
21%
Netherlands
21%
Population-based Cohort Study
21%
Total Thrombus-formation Analysis System
21%
Graft-versus-host Disease (GvHD)
21%
Enteropathy-associated T-cell Lymphoma
21%
Immunosuppression
21%
Prospective Randomized Trial
21%
Ara-C
18%
Etoposide
18%
Confidence Interval
18%
Chemotherapy
16%
Hazard Ratio
16%
Adult T-cell Leukemia
11%
Peripheral T-cell Lymphoma
10%
Lymphoma Patients
10%
Whole Brain Radiotherapy
8%
Rituximab
8%
Mycophenolate Mofetil
7%
Cyclosporine
7%
Non-severe
7%
Treatment Regimen
5%
Thiotepa
5%
Mortality Risk
5%
Induction Regimen
5%
Low Incidence
5%
Lymphoma
5%
Elevated LDH
5%
Microfluidic Measurement
5%
Poor Prognosis
5%
Doxorubicin
5%
5-year Survival
5%
Primary Therapy
5%
Cyclophosphamide
5%
Period Analysis
5%
Limited-stage
5%
Predictors of Poor Prognosis
5%
Advanced Stage
5%
Advanced Stage Disease
5%
Cancer Registry
5%
Prednisone
5%
Medicine and Dentistry
Blood Stasis
27%
Bleeding Disorder
23%
Thrombosis
23%
Inflammatory Bowel Disease
21%
Faecal Calprotectin
21%
Drug Megadose
21%
Primary Central Nervous System Lymphoma
21%
Combination Chemotherapy
21%
Methotrexate
21%
Valemetostat
21%
Enteropathy-Associated T-Cell Lymphoma
21%
Blood Clotting
21%
Cohort Analysis
21%
Overall Survival
21%
Autologous Stem Cell Transplantation
19%
Etoposide
15%
Hazard Ratio
13%
Carmustine
9%
Crohn's Disease
9%
Ulcerative Colitis
9%
Peripheral T-Cell Lymphoma
8%
Bleeding Diathesis
7%
Rituximab
7%
Whole Brain Radiotherapy
7%
Structure Analysis
7%
Diseases
6%
Antiplatelet
6%
Antithrombotic
6%
Thrombocyte Function
6%
Disease Activity
6%
Endoscopy
6%
Laboratory Test
5%
Bleeding
5%
Diagnosis
5%